Phenotype-guided estimation

Estimate the cardiovascular direction of CPAP effect

Explore how published treatment-effect modifiers may shift cardiovascular outcomes in obstructive sleep apnea.

Pooled RCTs n=3,549Post hoc evidence
Research use only — not validated for bedside decisions
Evidence applicability
Blood pressurei
/mmHg
Study modifier<140 / <90
High-risk phenotype = HRR >9.4 or HB >87.1

High-risk phenotype · Matched subgroup

High-risk OSA phenotype • CPAP-associated benefit signal

HR 0.65 (95% CI 0.480.89)

The most specific matched subgroup favored CPAP for MACCE prevention.

Favors CPAPNo effectFavors control
0.250.5124

Hazard ratio (log scale)

What the calculator can reproduce

Published subgroup estimates

The calculator applies the phenotype definition and the most specific matching hazard ratio reported by Azarbarzin and colleagues. It does not refit or extrapolate the trial data.

CPAP versus usual care for major adverse cardiovascular and cerebrovascular events
Matched populationHigh-risk OSALow-risk OSAInterpretation
All participants0.83 (0.66–1.05)1.22 (0.96–1.54)Both CIs include 1.0
Epworth <110.76 (0.60–0.98)1.30 (1.01–1.66)Benefit/harm directions separate
BP <140/900.72 (0.54–0.95)1.33 (1.00–1.76)Lower CI bound is 1.00 for low risk
Epworth <11 + BP <140/900.65 (0.48–0.89)1.35 (1.00–1.82)Most specific secondary subgroup
>9.4 bpm

Heart-rate response

Mean pulse-rate rise following individual respiratory events.

OR
>87.1 %·min/h

Hypoxic burden

Event-associated desaturation area multiplied by apnea-hypopnea index.

High-risk OSA phenotype

Meeting either threshold classified a participant as high risk in the pooled analysis.

Second-paper context

Causal-forest feature review

Cohen and colleagues used 23 interacting features. The paper does not publish a deployable model object or sufficient weights to reproduce an individualized treatment-effect score, so this panel is descriptive—not a second calculator.

Enter available SAVE-model features

Values are compared with reported tertile summaries; they are never combined into a score.

No causal-forest score generatedOriginal fitted model required

How these features appeared in reported tertiles

  • Absent

    Prior MI was more prevalent in the harm tertile: 39.7% vs 30.6% in benefit.

  • Absent

    Prior revascularization was more prevalent in harm: 40.1% vs 30.2%.

  • Present

    Prior stroke was more prevalent in benefit: 46.7% vs 41.1%, with p=0.059.

  • never

    Smoking status differed across tertiles; never-smoking was most common in benefit.

Your valueBenefit meanHarm mean
AHI 2727.329.6
ODI 2626.028.9
T90 14%14.2%17.2%
HR SD 5.85.85.2

The authors explicitly note that isolated linear relationships cannot explain the causal forest. Similarity to a tertile mean must not be interpreted as an individual prediction.

Methods & safeguards

What this tool does—and does not do

01

Classifies the published phenotype

High risk requires heart-rate response >9.4 bpm or hypoxic burden >87.1 %·min/h. Strict inequalities match the paper.

02

Matches the narrowest subgroup

Epworth and blood-pressure inputs select the most specific applicable row from the published pooled-RCT table.

03

Reports—not predicts

The displayed hazard ratio is a subgroup estimate. It is not a personalized absolute risk, probability, or validated bedside recommendation.

Clinical guardrails

  • Do not initiate, withhold, or stop CPAP based on this website.
  • The evidence concerns cardiovascular outcomes in people with established cardiovascular disease; symptom relief and other CPAP indications are outside this estimator.
  • Both analyses were post hoc; the causal-forest model lacked external validation, and the pooled-trial population was predominantly male and generally non-sleepy.
  • Heart-rate response and hypoxic burden require event-linked sleep-study processing and should not be substituted with resting pulse or simple time below 90%.

Primary sources

Evidence used

Azarbarzin et al.Cardiovascular benefit of CPAP according to high-risk obstructive sleep apnoea: a multi-trial analysisEuropean Heart Journal, 2026 ↗Cohen et al.Individualized treatment effects of CPAP on secondary cardiovascular outcomes in non-sleepy OSA patientsCommunications Medicine, 2026 ↗